Regulatory Updates on Biosimilars

Competitions and/or success in the present pharma industry are determined by the winning patent strategy which mostly pertains to the generic market entry. Generic and branded drug manufacturers both the patent strategy proximally belongs to the Hatch-Waxman Act statutory scheme and ANDA litigations. The Hatch-Waxman Act enacted in 1984 with amendment in 2003 facilitated the entry of generics at an early stage-thereby finishing the battle of branded generic ANDA of blockbuster drugs. All the same the Biologics Price Competition and Innovation (BPCI) Act has maximized the branded-generic patent duel in the biologics realm by imposing a litigated framework on follow-on-biologics.

An FDA analysis of drug prices from 1999 to 2004 found that the discount from generic competition was just 6% with one generic competitor, but jumps to 48% with two generic competitors, 56% with three, 61% with four and 67% with five generic producers in a market. Within 2 years of the expiration of the patent of the popular drug Zantac in 1997, generics of Zantac accounted 90% of the treatment’s total sales, and the price for patients was about 10% of its pre-generic price. European patents on biologic treatments began to expire in 2000, and in April 2006, Sandoz and Biopartners successfully received EMEA approval for the first European biogenerics, two products containing human growth hormone.

    Related Conference of Regulatory Updates on Biosimilars

    July 25-26, 2024

    34th Annual European Pharma Congress

    Frankfurt, Germany
    August 06-07, 2024

    27th World Congress on Nursing, Pharmacology and Healthcare

    Aix-en-Provence, France
    August 28-29, 2024

    4th International Conference on Pharmaceutical Chemistry

    Aix-en-Provence, France
    September 11-12, 2024

    9th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    September 25-26, 2024

    4th World Congress on Rare Diseases & Orphan Drugs

    Paris, France
    October 31-01, 2024

    37th World Congress on Pharmacology

    Amsterdam, Netherlands
    November 26-27, 2024

    3rd World Conference on Pharma Industry and Medical Devices

    Zurich, Switzerland
    November 26-27, 2024

    3rd World Congress on Precision and Personalized Medicine

    Zurich, Switzerland
    November 28-29, 2024

    12th International Conference on Clinical Trials

    Vancouver, Canada
    November 28-29, 2024

    39th World Congress on Pharmacology and Therapeutics

    Paris, France
    December 05-06, 2024

    17th World Drug Delivery Summit

    Dubai, UAE
    March 13-14, 2025

    8th International on Pharmacy and Pharmaceutical Conference

    Prague, Czech Republic
    April 14-15, 2025

    18th European Biosimilars Congress

    Aix-en-Provence, France

    Regulatory Updates on Biosimilars Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in